

Sunday, 18 July 2010

17:30 - 18:45 OL Opening Lecture

OL Found in translation: human pharmacology comes of age
Jeffrey K Aronson (UK)

Monday, 19 July 2010

08:30 - 09:15 PL01 PLENARY LECTURE

PL01 Vascular endothelium: physiology, pharmacology and vascular disease
Salvador Moncada (UK)

08:30 - 09:15 PL02 PLENARY LECTURE

PL02 Biologics and good clinical practice in the European Union
Klaus Cichutek (Germany)

08:30 - 09:15 PL03 PLENARY LECTURE

PL03 Pharmacological control of central serotonin neurons
Trevor Sharp (UK)

09:30 - 12:30 FC01 CLINICAL PHARMACOLOGY IN THE EMERGING COUNTRIES

Leader: Lembit Rägo (Switzerland)

FC01.1 Clinical pharmacology and promotion of rational use of medicines in emerging and developing countries

Chair: Suzanne R Hill (Switzerland)

FC01.1.1 Clinical pharmacology in developing countries: overview of current status and future trends

Andrew Walubo (South Africa)

FC01.1.2 Promoting clinical pharmacology in developing countries through education and research training

Folke Sjöqvist (Sweden)

FC01.1.3 Update of the WHO publication on clinical pharmacology 1970: what we learned from the process and main outcomes

Simon RJ Maxwell (UK)

FC01.1.4 Is WHO's Essential Medicines List contributing to the rational use in developing countries?

Andrew Loftis Gray (South Africa)

09:30 - 12:30 FC02 TRANSMEMBRANE TRANSPORT: PERSPECTIVES FOR DISEASE AND DRUG DISCOVERY

Leaders: Randy Blakely (USA) & Richard Kim (Canada)

FC02.1 Molecular structure and pharmacology of membrane transporters

Chairs: Ulrik Gether (Denmark) & Jonathan A Javitch (USA)

FC02.1.1 Molecular pharmacology of SLC6 neurotransmitter transporters

Ulrik Gether (Denmark)

FC02.1.2 Mechanisms of sodium-coupled transport

Jonathan A Javitch (USA)

FC02.1.3 Structure and function of ABC transporters in health and disease

Michael M Gottesman (USA)

FC02.1.4 Molecular pharmacology and function of the breast cancer resistance protein (ABCG2)

Hendrik van Veen (UK)

Monday, 19 July 2010

09:30 - 12:30 FC03 ION CHANNELS IN ANALGESIA AND ANAESTHESIA
Leaders: Clifford J Wolf (USA) & Nicholas Franks (UK)

FC03.1 Ion channel drug targets in the sensory nerve
Chairs: Peter McNaughton (UK) & Stephen G Waxman (USA)

FC03.1.1 Modulation of TRP channels: impact on pain sensation
Peter McNaughton (UK)

FC03.1.2 Voltage sensitive sodium channels in chronic pain states
Stephen G Waxman (USA)

FC03.1.3 Acid sensing ion channels in sensory perception
Eric Lingueglia (France)

FC03.1.4 TRP proteins on sensory nerves
Ardem Patapoutian (USA)

09:30 - 12:30 FC04 PHARMACOEPIDEMOLOGY, CURRENT CONTROVERSIES AND OPPORTUNITIES
Leaders: Bert Leufkens (The Netherlands) & Jesper Hallas (Denmark)

FC04.1 Methodological issues in pharmacoepidemiology
Chair: Jesper Hallas (Denmark) & Til Stürmer (USA)

FC04.1.1 Immortal and immeasurable time in pharmacoepidemiology
Samy Suissa (Canada)

FC04.1.2 Healthy initiators and sick stoppers
Robert J Glynn (USA)

FC04.1.3 Natural experiments in pharmacoepidemiology
Olaf H Klungel (The Netherlands)

FC04.1.4 Treatment decisions and propensity scores
Til Stürmer (USA)

09:30 - 12:30 FC05 TRANSLATIONAL SCIENCE IN THE METABOLIC SYNDROME: BASIC AND CLINICAL PHARMACOLOGY
(Sponsored by an unrestricted grant from Novo Nordisk A/S)
Leaders: Leif Groop (Sweden), Henning Beck-Nielsen (Denmark) & Jan-Erik Henriksen (Denmark)

FC05.1 New molecular targets in metabolic syndrome
Chairs: Jørgen Rungby (Denmark) & Anna Krook (Sweden)

FC05.1.1 Adipose tissue, reducing inflammation as a means of targeting the metabolic syndrome
Bjørn Richelsen (Denmark)

FC05.1.2 The muscle as a target for treatment of the metabolic syndrome
Anna Krook (Sweden)

FC05.1.3 Sodium glucose co-transporter 2 inhibitors in the treatment of hyperglycaemia
John PH Wilding (UK)

FC05.1.4 Solute carrier family 30 proteins as targets for beta-cell stimulation
Fabrice Chimienti (France)

Monday, 19 July 2010

09:30 - 12:30 FC06 THE HEART GONE WRONG; STABILIZATION OF CARDIAC FUNCTION *Leaders: Michael Sanguinetti (USA) & Lionel H Opie (South Africa)*

FC06.1 Molecular mechanisms of arrhythmia *Chairs: Michael Sanguinetti (USA) & Søren-Peter Olesen (Denmark)*

- FC06.1.1 The cardiac hERG channel and arrhythmogenesis
Michael Sanguinetti (USA)
- FC06.1.2 Would modulating intracellular Ca be antiarrhythmic?
Penelope A Boyden (USA)
- FC06.1.3 Cardiac electrical remodelling in health and disease
David S Rosenbaum (USA)
- FC06.1.4 Pharmacological modulation of cardiac potassium channels
Søren-Peter Olesen (Denmark)

09:30 - 12:30 FC07 SIMULATION AND DATA MODELLING IN DRUG DEVELOPMENT. BETTER DRUGS FASTER? *Leader: Hartmut Derendorf (USA)*

FC07.1 Modelling and simulation – how and why *Chairs: Hans V Westerhoff (The Netherlands) & Erik Mosekilde (Denmark)*

- FC07.1.1 Multiscale modelling of living systems: towards drugs and therapy
Erik Mosekilde (Denmark)
- FC07.1.2 Hitting robustness
Hiroaki Kitano (Japan) (TBC)
- FC07.1.3 Hitting the rhythm
Albert Goldbeter (Belgium)
- FC07.1.4 Making systems biology drugs work
Birgit Schoeberl (USA)

09:30 - 12:30 FC08 DEVELOPMENTS IN THE TREATMENT OF SEXUAL DYSFUNCTION AND DISEASES OF THE LOWER URINARY TRACT *Leaders: Francois Giuliano (France) & Karl Erik Andersson (USA)*

FC08.1 Pharmacological treatment of erectile dysfunction *Chair: Petter Hedlund (Sweden)*

- FC08.1.1 Central and peripheral targets for treatment of sexual dysfunction
Petter Hedlund (Sweden) (TBC)
- FC08.1.2 Phosphodiesterase type 5 and inhibitors – an update
Jackie D Corbin (USA)
- FC08.1.3 Non-oral treatments of erectile dysfunction
Jeremy PW Heaton (Canada) (TBC)
- FC08.1.4 Perspectives for the future: treatment of erectile dysfunction including gene therapy and tissue engineering
Tom F Lue (USA) (TBC)

Monday, 19 July 2010

9:30 - 12:30 **FC09 INFLAMMATION AND IMMUNOPHARMACOLOGY:
NEW TOOLS FOR OLD DISEASES**
Leaders: Ian Adcock (UK), Frans Nijkamp (The Netherlands) & Salvador Moncada (UK)

FC09.1 Steroids and beyond: novel treatments for asthma and allergy
Chairs: Ian Adcock (UK) & Hiromasa Inoue (Japan)

FC09.1.1 Improving current steroids
Ian Adcock (UK)

FC09.1.2 The mast cell as a target for new anti-asthma / allergy drugs
Christian Taube (Germany)

FC09.1.3 Effector and regulatory T cells in asthma
Cezmi A Akdis (Switzerland)

FC09.1.4 Suppressor of cytokine signaling in asthma
Hiromasa Inoue (Japan)

14:30 - 17:30 **FC01 CLINICAL PHARMACOLOGY IN THE EMERGING COUNTRIES**
Leader: Lembit Rägo (Switzerland)

FC01.2 Clinical pharmacology and drug regulation in resource limited settings
Chair: Alar Irs (Estonia)

FC01.2.1 Regulatory clinical pharmacologist – an ambassador of sanity
Alar Irs (Estonia)

FC01.2.2 Objective drug information versus advertising
Krisantha Weerasuriya (India)

FC01.2.3 Drug utilisation monitoring: planning interventions and guiding selection
Vera Vlahovic-Palcevski (Croatia)

FC01.2.4 Advise on drug reimbursement issues: a developing country perspective
Victor Zarate (Chile)

14:30 - 17:30 **FC02 TRANSMEMBRANE TRANSPORT: PERSPECTIVES FOR DISEASE
AND DRUG DISCOVERY**
Leaders: Randy Blakely (USA) & Richard Kim (Canada)

FC02.2 Membrane transporters and disease
Chairs: Søren Nielsen (Denmark) & Heidrun Potschka (Germany)

FC02.2.1 ABC transporters in adaptive immunity
Robert Tampe (Germany)

FC02.2.2 Aquaporines and disease
Søren Nielsen (Denmark)

FC02.2.3 Multidrug resistance in human epilepsy
Heidrun Potschka (Germany)

FC02.2.4 Vesicular transporters and CNS disease
Robert H Edwards (USA)

Monday, 19 July 2010

14:30 - 17:30 FC03 ION CHANNELS IN ANALGESIA AND ANAESTHESIA

Leaders: Clifford J Wolf (USA) & Nicholas Franks (UK)

FC03.2 Voltage-operated calcium channels as targets for analgesic action

Chairs: Annette Dolphin (UK) & Terrance P Snutch (Canada)

FC03.2.1 Effects of gabapentinoids on voltage dependent calcium channels

Annette Dolphin (UK)

FC03.2.2 CaV(2) channels as targets for drug action

Terrance P Snutch (Canada)

FC03.2.3 Pharmacological regulation of T-type calcium channels in peripheral pain pathways

Slobodan M Todorovic (USA)

FC03.2.4 Identification of T-type calcium channel blockers

Emmanuel Bourinet (France)

14:30 - 17:30 FC04 PHARMACOEPIDEMOLOGY, CURRENT CONTROVERSIES AND OPPORTUNITIES

Leaders: Bert Leufkens (The Netherlands) & Jesper Hallas (Denmark)

FC04.2 Advanced methods for signal generating in claims databases

Chair: Andrew Bate (Sweden)

FC04.2.1 Methods for screening longitudinal electronic healthcare records

Andrew Bate (Sweden)

FC04.2.2 The US based Sentinel Initiative – status, potential and future possibilities

Hugh H Tilson (USA) (TBC)

FC04.2.3 The Observational Medical Outcomes Partnership (OMOP) initiative. What it is, its importance and results so far

Paul Stang (USA)

FC04.2.4 An international perspective on screening for adverse effects of drugs and vaccines – how far can and should active surveillance go?

Stephen JW Evans (UK)

14:30 - 17:30 FC05 TRANSLATIONAL SCIENCE IN THE METABOLIC SYNDROME: BASIC AND CLINICAL PHARMACOLOGY

(Sponsored by an unrestricted grant from Novo Nordisk A/S)

Leaders: Leif Groop (Sweden), Henning Beck-Nielsen (Denmark) &

Jan-Erik Henriksen (Denmark)

FC05.2 Translational science in the metabolic syndrome: basic and clinical pharmacology

Chairs: Hans Erik Bøtker (Denmark) & Patricia Iozzo (Finland)

FC05.2.1 Insulin resistance: marker or mediator of increased cardiovascular risk?

Heinrich Taegtmeyer (USA)

FC05.2.2 Pathophysiology and treatment of heart failure in patients with type 2 DM

Paolo G Camici (UK)

FC05.2.3 Antithrombotic treatment in patients with type 2 DM

Steen Dalby Kristensen (Denmark)

FC05.2.4 Polypharmacy in type2 DM

Janne T Backman (Finland)

Monday, 19 July 2010

14:30 - 17:30 **FC06 THE HEART GONE WRONG; STABILIZATION OF CARDIAC FUNCTION**
Leaders: Michael Sanguinetti (USA) & Lionel H Opie (South Africa)

FC06.2 Novel anti-arrhythmics
Chairs: Stanley Nattel (Canada) & Leif Carlsson (Sweden)

- FC06.2.1 Mechanisms of atrial fibrillation
Stanley Nattel (Canada)
- FC06.2.2 Novel principles for pharmacological treatment of atrial fibrillation
Leif Carlsson (Sweden)
- FC06.2.3 Dronedarone for control of ventricular rate during atrial fibrillation: the ERATO study
Jean-Marc Davy (France)
- FC06.2.4 Vernakalant—a therapy for conversion of recent-onset atrial fibrillation
Denis Roy (Canada)

14:30 - 17:30 **FC07 SIMULATION AND DATA MODELLING IN DRUG DEVELOPMENT. BETTER DRUGS FASTER?**
Leader: Hartmut Derendorf (USA)

FC07.2 Disease models – using virtual organs and patient populations
Chairs: Hartmut Derendorf (USA) & Amin Rostami-Hodjegan (UK)

- FC07.2.1 Can we predict pharmacokinetics (PK) in disease populations?
Amin Rostami-Hodjegan (UK)
- FC07.2.2 Integrated models for the glucose – insulin system
Mats O Karlsson (Sweden)
- FC07.2.3 Heart modelling in drug development
Blanca Rodriguez (UK)
- FC07.2.4 From circadian control of PK/PD to personalized cancer chemotherapy
Francis Lévi (France)

14:30 - 17:30 **FC08 DEVELOPMENTS IN THE TREATMENT OF SEXUAL DYSFUNCTION AND DISEASES OF THE LOWER URINARY TRACT**
Leaders: Francois Giuliano (France) & Karl Erik Andersson (USA)

FC08.2 Treatment of sexual dysfunction associated with cardiovascular disease
Chairs: Ulf Simonsen (Denmark) & Graham Jackson (UK)

- FC08.2.1 Animal models for sexual dysfunction and cardiovascular disease
Delphine Behr-Roussel (France)
- FC08.2.2 Rho kinase inhibitors, cardiovascular and sexual function
Kanchan Chitale (USA)
- FC08.2.3 Association of erectile dysfunction and cardiovascular disease
Graham Jackson (UK)
- FC08.2.4 Effects of cardiovascular drugs on sexual function
Javier Angulo (Spain)

Monday, 19 July 2010

**14:30 - 17:30 FC09 INFLAMMATION AND IMMUNOPHARMACOLOGY:
NEW TOOLS FOR OLD DISEASES**
Leaders: Ian Adcock (UK), Frans Nijkamp (The Netherlands) & Salvador Moncada (UK)

FC09.2 Biologicals in inflammatory diseases - successes, promises and problems
Chairs: Marc Feldmann (UK) & Tom WJ Huizinga (The Netherlands)

- FC09.2.1 TNF-alpha antagonists – translating molecular insights in autoimmunity into effective therapy
Marc Feldmann (UK)
- FC09.2.2 Novel biologicals in the treatment of rheumatoid arthritis – abatacept, rituximab, IL-6 antagonists and beyond
Tom WJ Huizinga (The Netherlands)
- FC09.2.3 Immunomodulatory drugs in multiple sclerosis – from interferon alpha to specific monoclonal antibodies
Roland Martin (Germany)
- FC09.2.4 Immunogenicity and other problems in the use of biologicals
Michael G Tovey (France)

17:30 - 18:15 PL04 PLENARY LECTURE

PL04 The challenges of the pharmaceutical industry in the 21st century (preliminary title)
Emmanuel Canet (France)

17:30 - 18:15 PL05 PLENARY LECTURE

PL05 Cell therapy
Stephanie Dimmeler (Germany)

17:30 - 18:15 PL06 PLENARY LECTURE

PL06 The complex effects of 5-hydroxytryptamine in the cardiovascular system
Carlos Villalon (Mexico)

19:30 RECEPTION AT CITY HALL

Tuesday, 20 July 2010

08:30 - 09:15 PL07 EACPT PLENARY LECTURE

PL07 Personalized medicine beyond pharmacogenetics
Matthias Schwab (Germany)

08:30 - 09:15 PL08 PLENARY LECTURE

PL08 The Health Impact Fund
Thomas Pogge (USA)

08:30 - 09:15 PL09 PLENARY LECTURE

PL09 Antioxidants & free radicals, good or bad?
Barry Halliwell (Singapore)

08:30 - 09:15 FC01 CLINICAL PHARMACOLOGY IN EMERGING AND DEVELOPING COUNTRIES

Leader: Lembit Rägo (Switzerland)

FC01.3 Clinical trials in countries with developing and emerging economies

Chair: Lembit Rägo (Switzerland)

FC01.3.1 Global drug development in Singapore: regulatory perspective
Yang-Tong Foo (Singapore)

FC01.3.2 Ethical issues related to the clinical trials outside ICH regions
Juntra Karbwang-Laothavorn (Switzerland)

FC01.3.3 Clinical trials in resource and infrastructure poor settings: a view point from an investigator in the field
Kwablah Awadzi (Ghana) (TBC)

FC01.3.4 Clinical trials registries in countries with emerging and developing economies: impact to the clinical research
Davina Ghersi (Switzerland)

09:30 - 12:30 FC02 TRANSMEMBRANE TRANSPORT: PERSPECTIVES FOR DISEASE AND DRUG DISCOVERY

Leaders: Randy Blakely (USA) & Richard Kim (Canada)

FC02.3 Intestinal and hepatic transporters

Chairs: Richard B Kim (Canada) & Martin F Fromm (Germany)

FC02.3.1 Organic anion transporting polypeptide (OATP) transporters
Richard B Kim (Canada)

FC02.3.2 Transporter-mediated drug-interactions
Martin F Fromm (Germany)

FC02.3.3 Peptide transporters
Hannelore Daniel (Germany)

FC02.3.4 SLC6 amino acid transporters
Stefan Bröer (Australia)

09:30 - 12:30 FC03 ION CHANNELS IN ANALGESIA AND ANAESTHESIA

Leaders: Clifford J Woolf (USA) & Nicholas Franks (UK)

FC03.3 Synaptic plasticity in analgesia-related pathways

Chairs: Clifford J Woolf (USA) & MacDonald J Christie (Australia)

FC03.3.1 Selectively targeting ion channels for analgesia
Clifford J Woolf (USA)

FC03.3.2 Cellular neuroadaptations to chronic opioids
MacDonald J Christie (Australia)

FC03.3.3 NMDA receptors and chronic pain hypersensitivity
Mike Salter (Canada)

FC03.3.4 Synaptic dis-inhibition in chronic pain states
Hans Ulrich Zeilhofer (Switzerland)

Tuesday, 20 July 2010

09:30 - 12:30 FC04 PHARMACOEPIDEMOLOGY, CURRENT CONTROVERSIES AND OPPORTUNITIES

Leaders: Bert Leufkens (The Netherlands) & Jesper Hallas (Denmark)

FC04.3 Regulatory challenges in managing risk of medicinal products

Chair: Bert Leufkens (The Netherlands)

FC04.3.1 What are the issues driving the regulatory agenda on drug safety and risk management?

June M Raine (UK)

FC04.3.2 Are the available research methods sufficiently valid to address current benefit-risk issues on medicinal products?

Stephen JW Evans (UK)

FC04.3.3 New approaches to fill the methods gap in pharmacovigilance

Marieke de Bruin (The Netherlands)

FC04.3.4 Is science enough to enforce appropriate regulatory decision making on drug safety?

TBA

09:30 - 12:30 FC05 TRANSLATIONAL SCIENCE IN THE METABOLIC SYNDROME: BASIC AND CLINICAL PHARMACOLOGY

(Sponsored by an unrestricted grant from Novo Nordisk A/S)

Leaders: Leif Groop (Sweden), Henning Beck-Nielsen (Denmark) & Jan-Erik Henriksen (Denmark)

FC05.3 Normalizing blood glucose in metabolic syndrome I: GLP-1 analogues and DPP IV inhibitors

Chairs: Jens Juul-Holst (Denmark) & Michael A Nauck (Germany)

FC05.3.1 The GIP-₁ receptor as a target for treatment of diabetes

Lotte Bjerre Knudsen (Denmark)

FC05.3.2 Incretin mimetics 2010: The safety experience

David M Kendall (USA)

FC05.3.3 GLP-₁ secretion as a prerequisite for the antidiabetic activity of DPP-4 inhibitors: can it be modified?

Fiona M Gribble (UK)

FC05.3.4 Incretin-based medication and cardiovascular disease

Baptist Gallwitz (Germany)

09:30 - 12:30 FC06 THE HEART GONE WRONG; STABILIZATION OF CARDIAC FUNCTION

Leaders: Michael Sanguinetti (USA) & Lionel H Opie (South Africa)

FC06.3 Novel treatments for systolic heart failure

Chairs: Lionel H Opie (South Africa) & Kenneth R Chien (USA) (TBC)

FC06.3.1 Metabolic perturbations, modulators and cardiac function

Lionel H Opie (South Africa)

FC06.3.2 New therapeutic targets in heart failure

Kenneth R Chien (USA) (TBC)

FC06.3.3 Effects of serotonin in the failing ventricle: potential therapeutic implications

Finn Olav Levy (Norway)

FC06.3.4 Phosphodiesterases and chronic heart failure

David A Kass (USA)

Tuesday, 20 July 2010

09:30 - 12:30 FC07 **SIMULATION AND DATA MODELLING IN DRUG DEVELOPMENT. BETTER DRUGS FASTER?**
Leader: Hartmut Derendorf (USA)

FC07.3 Modelling and simulation in clinical drug development
Chair: Hans-Günter Schäfer (Germany)

FC07.3.1 Modelling and simulation in clinical drug development at Boehringer
Hans-Günter Schäfer (Germany)

FC07.3.2 Modelling and simulation in clinical drug development at Bristol-Myers
Marc Pfister (USA)

FC07.3.3 Modelling and simulation in clinical drug development at Pfizer
Sriram Krishnaswami (USA)

FC07.3.4 Modelling and simulation in clinical drug development at Novartis
Donald Stanski (Switzerland) (TBC)

09:30 - 12:30 FC08 **DEVELOPMENTS IN THE TREATMENT OF SEXUAL DYSFUNCTION AND DISEASES OF THE LOWER URINARY TRACT**
Leaders: Francois Giuliano (France) & Karl Erik Andersson (USA)

FC08.3 Pharmacological treatment of lower urinary tract syndrome/benign prostatic hyperplasia
Chairs: Petter Hedlund (Sweden) & Francois Giuliano (France)

FC08.3.1 Central pharmacological targets for the treatment of ejaculatory disorders
Francois Giuliano (France)

FC08.3.2 Sensory functions as a basis for symptoms and therapy in the overactive bladder
Karl Erik Andersson (USA)

FC08.3.3 GnRH antagonists - from basic science to the clinic in BPH and overactive bladder
Enrico Colli (Denmark)

FC08.3.4 BPH – beyond alpha-adrenoceptors and 5 α -reductase
Christian Gratzke (Germany)

09:30 - 12:30 FC09 **INFLAMMATION AND IMMUNOPHARMACOLOGY: NEW TOOLS FOR OLD DISEASES**
Leaders: Ian Adcock (UK), Frans Nijkamp (The Netherlands) & Salvador Moncada (UK)

FC09.3 iNOS - nitric oxide pathway in inflammation and as a target of anti-inflammatory treatment
Chairs: Eeva Moilanen (Finland) & Salvador Moncada (UK)

FC09.3.1 NO as a factor in inflammation
Eeva Moilanen (Finland)

FC09.3.2 Exhaled NO in the diagnosis and therapy monitoring of inflammatory airway disease
Kjell Alving (Sweden)

FC09.3.3 Nitrosative stress in inflammation
David A Wink (USA)

FC09.3.4 iNOS inhibitors in inflammatory diseases: lessons from animal and human studies
Richard G Knowles (UK)

FC09.3.5 NO, mitochondrial function and tissue injury in inflammation and septic shock
Salvador Moncada (UK)

Tuesday, 20 July 2010

14:30 - 17:30 FC01 CLINICAL PHARMACOLOGY IN EMERGING AND DEVELOPING COUNTRIES

Leader: Lembit Rägo (Switzerland)

FC01.4 Pharmacovigilance in emerging and developing countries: a luxury or a must?

Chairs: Ambrose O Isah (Nigeria)

FC01.4.1 Specific features of medicines safety and pharmacovigilance in Africa

Ambrose O Isah (Nigeria)

FC01.4.2 Pharmacovigilance in China: recent progress and future challenges

TBA

FC01.4.3 Pharmacovigilance as part of regulatory framework: Brazilian experience

Murilo Freitas Dias (Brazil)

FC01.4.4 WHO Programme for International Drug Monitoring as an effective framework for strengthening national pharmacovigilance systems

Lembit Rägo (Switzerland)

14:30 - 17:30 FC02 TRANSMEMBRANE TRANSPORT: PERSPECTIVES FOR DISEASE AND DRUG DISCOVERY

Leaders: Randy Blakely (USA) & Richard Kim (Canada)

FC02.4 Membrane transporters: Molecular genetics and pharmacogenetics

Chairs: Randy Blakely (USA) & Ingolf Cascorbi (Germany)

FC02.4.1 SLC6 neurotransmitter transporters

Randy Blakely (USA)

FC02.4.2 Quantitative structure-activity relationship of ABC-transporters

Toshiyuki Sakaeda (Japan) (TBC)

FC02.4.3 Clinical consequences of transporter variants

Ingolf Cascorbi (Germany)

FC02.4.4 Regulation of drug transporters

Gerd Kullak-Ublick (Switzerland)

14:30 - 17:30 FC03 ION CHANNELS IN ANALGESIA AND ANAESTHESIA

Leaders: Clifford J Wolf (USA) & Nicholas Franks (UK)

FC03.4 Ion channels as molecular targets for general anaesthetics

Chairs: Nicholas Franks (UK) & Michel Lazdunski (France)

FC03.4.1 Ion channels as targets for general anaesthetics

Nicholas Franks (UK)

FC03.4.2 Two pore domain potassium channels as targets for general anaesthetics

Michel Lazdunski (France)

FC03.4.3 GABAA receptors as targets for general anaesthetics

Neil L Harrison (USA)

FC03.4.4 HCN channel subunit specific effects of general anaesthetics

Douglas A Bayliss (USA)

Tuesday, 20 July 2010

14:30 - 17:30 FC04 PHARMACOEPIDEMOLOGY, CURRENT CONTROVERSIES AND OPPORTUNITIES`

Leaders: Bert Leufkens (The Netherlands) & Jesper Hallas (Denmark)

FC04.4 In utero exposure to drugs

Chairs: Lolkje TW de Jong-van den Berg (The Netherlands) & Corinne de Vries (UK)

FC04.4.1 Determining drug effects - clinical considerations when establishing birth outcomes
Lolkje TW de Jong-van den Berg (The Netherlands)

FC04.4.2 The impact of thalidomide and its revival as a vital medicine. Lessons learned from history
Trent D Stephens (USA)

FC04.4.3 Pharmacological considerations of drug teratogenicity – why animal studies are not sufficient
Per Damkier (Denmark)

FC04.4.4 Unique methodological features in the pharmacoepidemiology of birth defects
Corinne de Vries (UK)

14:30 - 17:30 FC05 TRANSLATIONAL SCIENCE IN THE METABOLIC SYNDROME: BASIC AND CLINICAL PHARMACOLOGY

(Sponsored by an unrestricted grant from Novo Nordisk A/S)

Leaders: Leif Groop (Sweden), Henning Beck-Nielsen (Denmark) & Jan-Erik Henriksen (Denmark)

FC05.4 Normalizing blood glucose in metabolic syndrome II: glitazones and metformin
Chairs: Philip Home (UK) & Henning Beck-Nielsen (Denmark)

FC05.4.1 The role of metformin and glitazones in the regulation on hepatic glucose metabolism
Michael Roden (Germany)

FC05.4.2 Rosiglitazone: lessons from the RECORD study
Philip Home (UK)

FC05.4.3 Metformin: Lessons from UKPDS
Amanda Adler (UK)

FC05.4.4 Translational science in metabolic syndrome – future directions
Henning Beck-Nielsen (Denmark)

14:30 - 17:30 THE HEART GONE WRONG; STABILIZATION OF CARDIAC FUNCTION

Leaders: Michael Sanguinetti (USA) & Lionel H Opie (South Africa)

FC06.4 Treatment options for diastolic heart failure

Chairs: Douglas L Mann (USA) & Peter P Liu (Canada)

FC06.4.1 MicroRNAs, gene patterns and heart failure
Douglas L Mann (USA)

FC06.4.2 Diastolic heart failure requires different approaches
Peter P Liu (Canada)

FC06.4.3 Autophagy and apoptosis in heart failure
Kinya Otsu (Japan)

FC06.4.4 Rescuing a failing heart
Martin E Anderson (USA)

Tuesday, 20 July 2010

14:30 - 17:30 FC07 SIMULATION AND DATA MODELLING IN DRUG DEVELOPMENT. BETTER DRUGS FASTER?
Leader: Hartmut Derendorf (USA)

FC07.4 Modelling and simulation – a regulator's view
Chairs: Jogarao VS Gobburu (USA)

- FC07.4.1 Role of modelling and simulation at the FDA
Jogarao VS Gobburu (USA)
- FC07.4.2 Role of modelling and simulation at the EMEA
Franz König (UK)
- FC07.4.3 Role of modelling and simulation for drug approval in Asia
Yuki Ando (TBC)
- FC07.4.4 Disease modelling from a regulatory view **(Preliminary title)**
Siv Jönsson (Sweden)

14:30 - 17:30 FC08 DEVELOPMENTS IN THE TREATMENT OF SEXUAL DYSFUNCTION AND DISEASES OF THE LOWER URINARY TRACT
Leaders: Francois Giuliano (France) & Karl Erik Andersson (USA)

FC08.4 Pharmacological treatment of bladder dysfunction
Chairs: Karl Erik Andersson (USA) & Mark T Nelson (USA)

- FC08.4.1 Molecular mechanisms of bladder dysfunction
George J Christ (USA)
- FC08.4.2 Modulation of electromechanical coupling in the bladder
Christopher H Fry (UK)
- FC08.4.3 K channel modulation of bladder contractility
Mark T Nelson (USA)
- FC08.4.4 Botulinum toxin treatment for overactive bladder
Marcus John Drake (UK)

14:30 - 17:30 FC09 INFLAMMATION AND IMMUNOPHARMACOLOGY: NEW TOOLS FOR OLD DISEASES
Leaders: Ian Adcock (UK), Frans Nijkamp (The Netherlands) & Salvador Moncada (UK)

FC09.4 NSAIDs and COX-2 inhibitors. Current strategies and future directions
Chairs: Jane A Mitchell (UK) & Per-Johan Jakobsson (Sweden)

- FC09.4.1 Anti-inflammatory benefits and cardiovascular toxicity of NSAIDs and COX-2 inhibitors
Jane A Mitchell (UK)
- FC09.4.2 Endocannabinoids and beyond. Paracetamol, NSAIDs and novel mechanisms to treat inflammatory pain
Peter Zygmunt (Sweden)
- FC09.4.3 COX-2 and cancer
TBA
- FC09.4.4 Inhibitors of PGE synthases
Per-Johan Jakobsson (Sweden)

17:30 - 18:15 IUL IUPHAR LECTURE
The 50-Years IUPHAR Anniversary
Paul M Vanhoutte (PR China)

18:30 IUPHAR GENERAL ASSEMBLY

Wednesday, 21 July 2010

08:30 - 09:15 PL10 ASPET PLENARY LECTURE

PL10 Structure and function of the GPCR
Brian Kobilka (USA)

08:30 - 09:15 PL11 PLENARY LECTURE

PL11 Calcium and cell functions
Masamitsu Iino (Japan)

08:30 - 09:15 PL12 PLENARY LECTURE

PL12 Meeting the challenge of antibiotic resistance
Otto Cars (Sweden)

09:30 - 12:30 FC09 INFLAMMATION AND IMMUNOPHARMACOLOGY: NEW TOOLS FOR OLD DISEASES

Leaders: Ian Adcock (UK), Frans Nijkamp (The Netherlands) & Salvador Moncada (UK)

FC09.5 Novel anti-inflammatory targets and mechanism

Chairs: Frans P Nijkamp (The Netherlands) & J Edwin Blalock (USA)

FC09.5.1 Dendritic cells as target for immunomodulation
Guy G Brusselle (Belgium)

FC09.5.2 CXC chemokines and antagonists in chronic inflammation
Gert Folkerts (The Netherlands)

FC09.5.3 Neuro-immune interactions in health and disease
J Edwin Blalock (USA)

FC09.5.4 Toll-like receptors as new targets for immune disorders
Luke AJ O'Neill (Ireland)

09:30 - 12:30 FC10 DRUGS FOR HALF THE WORLD: PAEDIATRIC CLINICAL PHARMACOLOGY

Leader: John N van den Anker (USA)

FC10.1 Innovative methodological approaches in drug development in children

Chair: Gérard Pons (France)

FC10.1.1 Place of the innovative methodological approaches in the development of medicinal products in children
Gérard Pons (France)

FC10.1.2 Increasing role of the observational approaches in the assessment of safety and efficacy of medicinal products in children
Emilio J Sanz (Spain)

FC10.1.3 Specificities of clinical trials in developing countries : malaria
Karen I Barnes (South Africa)

FC10.1.4 Specificities of clinical trials in adolescent girls: contraception and abortion
Viveca Odling (Sweden)

Wednesday, 21 July 2010

09:30 - 12:30 FC11 **G PROTEIN-COUPLED γ TM RECEPTORS: FROM MOLECULAR TO PHYSIOLOGICAL FUNCTION**

Leaders: Brian K Kobilka (USA) & Jean-Philippe Pin (France)

FC11.1 γ TM receptor structure

Chairs: Gebhard FX Schertler (UK)

FC11.1.1 New G-protein-coupled receptor crystal structures: insights and limitations
Gebhard FX Schertler (UK)

FC11.1.2 Ligand binding and micro-switches in γ TM receptor structures
Thue W Schwartz (Denmark)

FC11.1.3 Crystal structure of opsin in its G-protein-interacting conformation
Klaus Peter Hofmann (Germany)

FC11.1.4 Structure of extracellular ligand binding domains in metabotropic glutamate receptors
Hisato Jingami (Japan)

09:30 - 12:30 FC12 **ION CHANNELOPATHIES: NEW WINDOWS ON COMPLEX DISEASE AND THERAPY**

Leader: William A Catterall (USA)

FC12.1 Ion channelopathies in the brain: inherited epilepsy and migraine

Chairs: William A Catterall (USA) & Daniela Pietrobon (Italy)

FC12.1.1 Sodium channelopathies and epilepsy
Ingrid Scheffer (Australia)

FC12.1.2 Mechanisms of hyperexcitability and co-morbidities in severe myoclonic epilepsy of infancy
William A Catterall (USA)

FC12.1.3 Functional effects of sodium channel mutations in inherited epilepsy and migraine
Massimo Mantegazza (Italy)

FC12.1.4 Gain-of-function mutations of calcium channels in familial hemiplegic migraine
Daniela Pietrobon (Italy)

09:30 - 12:30 **MAXIMISING BENEFITS AND MINIMIZING HARMS FROM DRUGS**

Leaders: Munir Pirmohamed (UK) & B Kevin Park (UK)

FC13.1 Drug safety: the epidemiology

Chairs: Kees van Grootheest (The Netherlands) & Alasdair Breckenridge (UK)

FC13.1.1 Adverse drug reactions in hospitals
Kees van Grootheest (The Netherlands)

FC13.1.2 An industry perspective of drug safety
Michael A Ibara (USA)

FC13.1.3 Drug regulation and drug safety
Alasdair Breckenridge (UK)

FC13.1.4 Clinical toxicology perspective of drug safety
Simon Thomas (UK)

Wednesday, 21 July 2010

09:30 - 12:30 FC14 ADDICTION AND DOPING: NEUROBIOLOGICAL AND CLINICAL BASIS OF EMERGING TREATMENTS

Leaders: Markus Heilig (USA) & Yavin Shaham (USA)

FC14.1 Pharmacological treatment of opiate dependence - much achieved, much left to do *Chairs: Sharon Walsh (USA) & Yasmin Hurd (USA)*

- FC14.1.1 Efficacy of current pharmacotherapies for opioid dependence: what challenges remain?
Sharon Walsh (USA)
- FC14.1.2 Neurobiological consequences of opioid exposure: Implications for pharmacotherapy development
Yasmin Hurd (USA)
- FC14.1.3 Opioid polymorphisms: What is their role in expression of opioid dependence and response to treatment
Christopher Evans (USA)
- FC14.1.4 Global impact of opioid pharmacotherapy: beyond heroin dependence
Nicolas C Clark (Switzerland)

09:30 - 12:30 FC15 ENDOTHELIUM IN HEALTH AND DISEASE

Leaders: Christopher J Garland(UK) & Arthur Weston (UK)

FC15.1 Nitric oxide and oxidative stress *Chairs: Frank M Faraci (USA) & Christopher G Sobey (Australia)*

- FC15.1.1 NOS and vascular disease
Ralph Brandes (Germany)
- FC15.1.2 NOS, cerebral circulation and vascular disease
Frank M Faraci (USA)
- FC15.1.3 NOS, myocardial microvessels and mitochondria
Thomas H Hintze (USA)
- FC15.1.4 NADPH oxidase and therapeutic targeting
Christopher G Sobey (Australia)

09:30 - 12:30 FC16 NATURAL PRODUCTS: PAST AND FUTURE?

Leaders: Ricky Ying-Keung Man (PR China), Tai-Ping Fan (UK) & Zhi-bin Lin (PR China)

FC16.1 Cardioprotection by natural products *Chairs: Roberto Soares de Moura (Brazil) & David D Ku (USA)*

- FC16.1.1 Red wine polyphenols
Valerie Schini-Kerth (France)
- FC16.1.2 Dark chocolate
Thomas F Lüscher (Switzerland)
- FC16.1.3 Garlic
David D Ku (USA)
- FC16.1.4 Fish oil and ω 3-unsaturated fatty acids
Hiroaki Shimokawa (Japan)

Wednesday, 21 July 2010

09:30 - 12:30 FC17 NEW APPROACHES AND TARGETS IN PSYCHIATRY

Leaders: David J Nutt (UK) & Birte Glenthøj (Denmark)

FC17.1 The pathophysiological basis for psychosis

Chairs: Anthony A Grace (USA) & Albert Gjedde (Denmark)

FC17.1.1 Hippocampal hyperactivity drives dopamine hyper-responsivity in an animal model of schizophrenia

Anthony A Grace (USA)

FC17.1.2 Cortical and subcortical dopamine receptor interactions in sensation-seeking

Albert Gjedde (Denmark)

FC17.1.3 Imaging the dopamine system in schizophrenia: Imbalance between cortical and subcortical dopamine regulation

Anissa Abi-Dargham (USA)

FC17.1.4 Altered glutamate regulation in schizophrenia

Lars V Kristiansen (Denmark)

09:30 - 12:30 FC18 NUCLEAR RECEPTOR TARGETS FOR TREATMENT OF DISEASES

Leaders: Bart Staels (France) & Vincent Laudet (France)

FC18.1 Nuclear receptors and metabolic control

Chairs: David J Mangelsdorf (USA) & Susanne Mandrup (Denmark)

FC18.1.1 Integration of lipid metabolism, inflammation and immunity by nuclear receptors

Peter Tontonoz (USA)

FC18.1.2 From metabolism to development via nuclear receptors

Béatrice Desvergne (France)

FC18.1.3 Nuclear Receptor Regulation of Feeding and Fasting

David J Mangelsdorf (USA)

FC18.1.4 PPARs and metabolic control in adipocytes

Susanne Mandrup (Denmark)

14:30 - 17:30 FC10 DRUGS FOR HALF THE WORLD: PAEDIATRIC CLINICAL PHARMACOLOGY

Leader: John N van den Anker (USA)

FC10.2 WHO and medicines in developing countries

Chair: Kalle Hoppu (Finland)

FC10.2.1 Introduction & background : why and how was the resolution WHA 60.20 better medicines for children born

Kalle Hoppu (Finland)

FC10.2.2 Essential medicines list for children and other activities related to paediatric medicines by the WHO

Suzanne R Hill (Switzerland)

FC10.2.3 Key problems of children's medicines in developing countries – a paediatric clinical pharmacologist view

Shalini Sri Ranganathan (Sri Lanka)

FC10.2.4 Case: use of old data and modern scientific methods to provide more rational dosing and FDC formulations of TB medicines for children

Gregory L Kearns (USA)

Wednesday, 21 July 2010

14:30 - 17:30 FC11 G PROTEIN-COUPLED 7TM RECEPTORS: FROM MOLECULAR TO PHYSIOLOGICAL FUNCTION

Leaders: Brian K Kobilka (USA) & Jean-Philippe Pin (France)

FC11.2 γ 7TM receptors: activation, inactivation and allosteric modulation
Chairs: Jean Philippe R Pin (France) & Thue W Schwartz (Denmark)

FC11.2.1 Metabotropic glutamate and GABA receptors: activation and dimerization
Jean Philippe R Pin (France)

FC11.2.2 Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Arthur Christopoulos (Australia)

FC11.2.3 Allosteric modulation of adenosine receptors
Adriaan P Ijzerman (The Netherlands)

FC11.2.4 Activation and inactivation of chemokine γ 7TM receptors
Mette M Rosenkilde (Denmark)

14:30 - 17:30 FC12 ION CHANNELOPATHIES: NEW WINDOWS ON COMPLEX DISEASE AND THERAPY

Leader: William A Catterall (USA)

FC12.2 Ion channelopathies of peripheral nerve and muscle: inherited pain and periodic paralysis
Chairs: Stephen G Waxman (USA) (TBC) & Karin Jurkat-Rott (Germany)

FC12.2.1 Functional effects of sodium channel mutations in inherited chronic pain syndromes
Stephen G Waxman (USA) (TBC)

FC12.2.2 Selective inhibition of sodium channels by gating modifier toxins
Theodore R Cummins (USA)

FC12.2.3 Leak-induced pathogenesis and treatment of periodic paralysis
Karin Jurkat-Rott (Germany)

FC12.2.4 Gating pore cation currents in hypokalemic and normokalemic periodic paralysis
Todd Scheuer (USA)

14:30 - 17:30 FC13 MAXIMISING BENEFITS AND MINIMIZING HARMS FROM DRUGS

Leaders: Munir Pirmohamed (UK) & B Kevin Park (UK)

FC13.2 Drug metabolism and drug toxicity
Chairs: Frank J Gonzalez (USA) & B Kevin Park (UK)

FC13.2.1 The use of humanized mice in the study of drug toxicity
Frank J Gonzalez (USA)

FC13.2.2 Chemically reactive metabolites: separating fiction from facts
B Kevin Park (UK)

FC13.2.3 The importance of studying mechanisms of cell death in toxicology
Sten Orrenius (Sweden)

FC13.2.4 Pharmacogenetics of drug metabolism – TPMT as a paradigm
William E Evans (USA)

Wednesday, 21 July 2010

14:30 - 17:30 FC14 ADDICTION AND DOPING: NEUROBIOLOGICAL AND CLINICAL BASIS OF EMERGING TREATMENTS

Leaders: Markus Heilig (USA) & Yavin Shaham (USA)

FC14.2 Pharmacological treatments of alcohol dependence – illusion or opportunity?

Chairs: Rainer Spanagel (Germany) & Barbara J Mason (USA)

- FC14.2.1 Targeting glutamate receptors – preclinical and clinical studies
Rainer Spanagel (Germany)
- FC14.2.2 Targeting GABA receptors: role of GABAergic drugs
Giovanni Addolorato (Italy)
- FC14.2.3 Targeting nicotinic receptors
Selena E Bartlett (USA)
- FC14.2.4 Gabapentin in alcoholism: from laboratory study to treatment
Barbara J Mason (USA)

14:30 - 17:30 FC15 ENDOTHELIUM IN HEALTH AND DISEASE

Leaders: Christopher J Garland(UK) & Arthur Weston (UK)

FC15.2 Endothelium-dependent hyperpolarization

Chairs: Chris J Garland (UK) & Arthur Weston (UK)

- FC15.2.1 SKCa and IKCa channels in myoendothelial signalling
Arthur Weston (UK)
- FC15.2.2 Endothelial microdomains and integration of arterial dilatation
Christopher J Garland (UK)
- FC15.2.3 The calcium-sensing receptor in blood pressure modulation
Jacob Tfelt-Hansen (Denmark)
- FC15.2.4 The function of calcium pulsars in endothelial cells
Mark T Nelson (USA)

14:30 - 17:30 FC16 NATURAL PRODUCTS: PAST AND FUTURE?

Leaders: Ricky Ying-Keung Man (PR China), Tai-Ping Fan (UK), & Zhi-bin Lin (PR China)

FC16.2 Products derived from one single plant with convincing pharmacological data in explaining their mechanism of action

Chairs: Yong-Xiang Zhang (PR China) & Rudolf Bauer (Austria)

- FC16.2.1 Pharmacological and clinical research on Lingzhi (Ganoderma) in China
Zhi-Bin Lin (PR China)
- FC16.2.2 Molecular actions of alkamides from Echinacea explaining their immunomodulatory activity
Rudolf Bauer (Austria)
- FC16.2.3 Memory retrieval improvement by Ptychopetalum olacoides, a traditional Amazonian medicine
Elaine Elisabetsky (Brazil)
- FC16.2.4 Pharmacological use of Borago officinalis
Anwari Hassul Gilani (Pakistan)

Wednesday, 21 July 2010

14:30 - 17:30 FC17 NEW APPROACHES AND TARGETS IN PSYCHIATRY

Leaders: David J Nutt (UK) & Birte Glenthøj (Denmark)

FC17.2 Exploring new targets in schizophrenia using translation science

Chairs: P Jeffrey Conn (USA) & Torgny H Svensson (Sweden)

FC17.2.1 Mutants in translation: can new models of schizophrenia provide new insight and targets?

John L Waddington (Ireland)

FC17.2.2 Biomarkers for translational science in schizophrenia

Peter J Uhlhaas (Germany)

FC17.2.3 Allosteric modulators

P Jeffrey Conn (USA)

FC17.2.4 What can we learn from the existing drugs with atypical profiles?

Torgny H Svensson (Sweden)

14:30 - 17:30 FC18 NUCLEAR RECEPTOR TARGETS FOR TREATMENT OF DISEASES

Leaders: Bart Staels (France) & Vincent Laudet (France)

FC18.2 Nuclear receptors, vascular function and inflammation

Chairs: Christopher K Glass (USA) & Bart Staels (France)

FC18.2.1 Nuclear receptor-dependent repression mechanisms that regulate inflammation

Christopher K Glass (USA)

FC18.2.2 PPARα and residual cardiovascular risk

Bart Staels (France)

FC18.2.3 Mineralocorticoid receptor and vascular function

John Funder (Australia)

FC18.2.4 NR4A nuclear receptors and vascular function

Carlie JM DeVries (The Netherlands)

17:30 - 18:15 PL13 PLENARY LECTURE

PL13 Headache

Jes Olesen (Denmark)

17:30 - 18:15 PL14 PLENARY LECTURE

PL14 Toll-like receptor and innate immunity

Shizuo Akira (Japan)

17:30 - 18:15 PL15 PLENARY LECTURE

PL15 Estrogen actions in the cardiovascular system

Sue P Duckles (USA)

Thursday, 22 July 2010

08:30 - 09:15 PL16 PLENARY LECTURE

PL16 Drug metabolism - past, present and future
Olavi Pelkonen (Finland)

08:30 - 09:15 PL17 PLENARY LECTURE

PL17 Therapeutic potential of vaccines in the management of hypertension
Morris J Brown (UK)

08:30 - 09:15 PL18 PLENARY LECTURE

PL18 Innovation in bioscience and pharmacology education
Ian E Hughes (UK)

09:30 - 12:30 FC10 DRUGS FOR HALF THE WORLD: PAEDIATRIC CLINICAL PHARMACOLOGY

Leader: John N van den Anker (USA)

FC10.3 Formulation issues

Chair: Jörg Breitzkreutz (Germany) & Klaus Rose (Switzerland)

FC10.3.1 End-user specifications for optimal paediatric formulations
Atieno Ojoo (Denmark)

FC10.3.2 Novel drug formulations for children
Jörg Breitzkreutz (Germany)

FC10.3.3 Adapting formulations for children
Anthony J Nunn (UK)

FC10.3.4 Taste assessment and taste masking
Catherine Tuleu (UK)

09:30 - 12:30 FC11 G PROTEIN-COUPLED 7TM RECEPTORS: FROM MOLECULAR TO PHYSIOLOGICAL FUNCTION

Leaders: Brian K Kobilka (USA) & Jean-Philippe Pin (France)

FC11.3 γ TM receptors: scaffolding and signalling mechanisms

Chairs: Michelle Bouvier (Canada) & Heidi E Hamm (USA)

FC11.3.1 G-protein-coupled receptors as oligomeric signaling machines
Michelle Bouvier (Canada)

FC11.3.2 Heterotrimeric G protein activation by G-protein-coupled receptors
Heidi E Hamm (USA)

FC11.3.3 Scaffolding of G protein coupled receptors
Laurant Fagni (France)

FC11.3.4 Recent methodological advances in the discovery of GPCR-associated protein complexes
Ralf Jockers (France)

Thursday, 22 July 2010

09:30 - 12:30 FC12 ION CHANNELOPATHIES: NEW WINDOWS ON COMPLEX DISEASE AND THERAPY

Leader: William A Catterall (USA)

FC12.3 Ion channelopathies in the cardiovascular system: inherited arrhythmia and hypertension

Chairs: Michael C Sanguinetti (USA) & Bernard C Rossier (Switzerland)

FC12.3.1 Molecular mechanisms of potassium channel dysfunction in long- and short-QT syndromes

Michael C Sanguinetti (USA)

FC12.3.2 Sodium channelopathies in cardiac arrhythmia

Alfred L George (USA)

FC12.3.3 Molecular mechanism of ryanodine receptor dysfunction in cardiac arrhythmia

Andrew R Marks (USA)

FC12.3.4 Liddle's disease and salt-dependent hypertension

Bernard C Rossier (Switzerland)

09:30 - 12:30 FC13 MAXIMISING BENEFITS AND MINIMIZING HARMS FROM DRUGS

Leaders: Munir Pirmohamed (UK) & B Kevin Park (UK)

FC13.3 Pharmacogenomics and adverse drug reactions

Chairs: Steven J Leeder (USA) & Munir Pirmohamed (UK)

FC13.3.1 The pharmacogenetics of drug hypersensitivity

Simon Mallal (Australia) (TBC)

FC13.3.2 Genetic predisposition to drug-induced liver toxicity

Ann K Daly (UK)

FC13.3.3 Severe adverse drug reactions in children

Steven J Leeder (USA)

FC13.3.4 Variability in response to anticoagulants

Munir Pirmohamed (UK)

09:30 - 12:30 FC14 ADDICTION AND DOPING: NEUROBIOLOGICAL AND CLINICAL BASIS OF EMERGING TREATMENTS

Leaders: Markus Heilig (USA) & Yavin Shaham (USA)

FC14.3 Craving and relapse to drug seeking: lessons from animal models and human brain imaging

Chairs: Peter W Kalivas (USA) & Yavin Shaham (USA)

FC14.3.1 The brain circuitry of drug relapse

Peter W Kalivas (USA)

FC14.3.2 The role of the drug environment in relapse to drug seeking: lessons from rat studies

Yavin Shaham (USA)

FC14.3.3 Imaging craving in human addicts: does it predict drug relapse?

Rajita Sinha (USA)

FC14.3.4 Incubation of cocaine craving in rats and humans

Lin Lu (PR China)

Thursday, 22 July 2010

09:30 - 12:30 FC15 **ENDOTHELIUM IN HEALTH AND DISEASE**
Leaders: Christopher J Garland(UK) & Arthur Weston (UK)

FC15.3 **Endothelium-mediated control of vascular tone**
Chairs: Paul M Vanhoutte (France) & David J Webb (UK)

- FC15.3.1 COX-₁ products
Michel Félétou (France)
- FC15.3.2 COX-₂ products
Yu Huang (PR China)
- FC15.3.3 Nucleotides
Joachim Jankowski (Germany)
- FC15.3.4 Endothelial 15-lipoxygenase eicosanoids
William B Campbell (USA)
- FC15.3.5 Endothelins
David J Webb (UK)

09:30 - 12:30 FC16 **NATURAL PRODUCTS: PAST AND FUTURE?**
Leaders: Ricky Ying-Keung Man (PR China), Tai-Ping Fan (UK), & Zhi-bin Lin (PR China)

FC16.3 **Products derived from one single plant with convincing pharmacological data in explaining their mechanism of action**
Chairs: Zhi-Bin Lin (PR China) & Tai-Ping Fan (UK)

- FC16.3.1 Defining the mechanism of action of Liuwei Dihuang Decoction with metabonomics
Yong-Xiang Zhang (PR China)
- FC16.3.2 Danshen diwan
Henry Sun (PR China)
- FC16.3.3 Danshen synergy with arsenic
Zhu Chen (PR China) (TBC)
- FC16.3.4 Choto-san and recognition behaviour
Kinzo Matsumoto (Japan)

09:30 - 12:30 FC17 **NEW APPROACHES AND TARGETS IN PSYCHIATRY**
Leaders: David J Nutt (UK) & Birte Glenthøj (Denmark)

FC17.3 **Clinical aspects of treatment with antipsychotics**
Chairs: Shitij Kapur (UK) & Birte Glenthøj (Denmark)

- FC17.3.1 Response prediction
Shitij Kapur (UK)
- FC17.3.2 Antipsychotics, dopamine & glutamate
Birte Glenthøj (Denmark)
- FC17.3.3 Personalized procognitive pharmacotherapy in schizophrenia
Andreas Meyer-Lindenberg (Germany)
- FC17.3.4 Cognitive enhancing treatment
Philip D Harvey (USA) (TBC)

Thursday, 22 July 2010

09:30 - 12:30 FC18 NUCLEAR RECEPTOR TARGETS FOR TREATMENT OF DISEASES
Leaders: Bart Staels (France) & Vincent Laudet (France)

FC18.3 Nuclear receptors in the CNS
Chairs: Michael T Heneka (Germany) & Gary E Landreth (USA)

- FC18.3.1 Glucocorticoid action in the brain and stress control during aging
Osborne F Almeida (Germany)
- FC18.3.2 Roles of PPAR γ in stroke
Jaroslav Aronowski (USA)
- FC18.3.3 PPAR γ modulation in neurodegenerative disease
Michael T Heneka (Germany)
- FC18.3.4 Liver X receptors as therapeutic targets in Alzheimer's Disease
Gary E Landreth (USA)

14:30 - 17:30 FC10 DRUGS FOR HALF THE WORLD: PAEDIATRIC CLINICAL PHARMACOLOGY
Leader: John N van den Anker (USA)

FC10.4 Pain in children
Chair: Dick Tibboel (The Netherlands)

- FC10.4.1 Postoperative pain in children; do we really need morphine?
Dick Tibboel (The Netherlands)
- FC10.4.2 Developmental pharmacology of immature organs
John N van den Anker (USA)
- FC10.4.3 Pain in the newborn especially the premature
Karel Allegaert (Belgium)
- FC10.4.4 Pain assessment methods in the newborn
Lena Hellström-Westas (Sweden)

14:30 - 17:30 FC11 G PROTEIN-COUPLED 7TM RECEPTORS: FROM MOLECULAR TO PHYSIOLOGICAL FUNCTION
Leaders: Brian K Kobilka (USA) & Jean-Philippe Pin (France)

FC11.4 γ 7TM receptors: genetic mouse models and disease
Chairs: Marc G Caron (USA) & Brigitte L Kieffer (France)

- FC11.4.1 Akt/GSK $_3$ signaling in the action of psychotropic drugs
Marc G Caron (USA)
- FC11.4.2 Pharmacology of pre- versus postsynaptic α_2 -adrenoceptors
Lutz Hein (Germany)
- FC11.4.3 Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity
Sadaf Farooqi (UK)
- FC11.4.4 Opioid receptors: genetic mouse models
Brigitte L Kieffer (France)

Thursday, 22 July 2010

14:30 - 17:30 FC12 ION CHANNELOPATHIES: NEW WINDOWS ON COMPLEX DISEASE AND THERAPY

Leader: William A Catterall (USA)

FC12.4 Ion channelopathies in endocrine systems

Chairs: Per-Olof Berggren (Sweden) & Louis J Ptacek (USA)

FC12.4.1 Calcium channels and insulin release

Per-Olof Berggren (Sweden)

FC12.4.2 Channelopathies of ATP-gated potassium channels and insulin release

Frances Ashcroft (UK)

FC12.4.3 ATP-gated potassium channels in skeletal and cardiac muscle

Colin G Nichols (USA)

FC12.4.4 Potassium channel mutations in Andersen-Tawil syndrome

Louis J Ptacek (USA)

14:30 - 17:30 FC13 MAXIMISING BENEFITS AND MINIMIZING HARMS FROM DRUGS

Leaders: Munir Pirmohamed (UK) & B Kevin Park (UK)

FC13.4 New technologies – will they help in developing safer drugs

Chairs: David B Goldstein (USA) & Roy Goodacre (UK)

FC13.4.1 Safety pharmacogenomics

David B Goldstein (USA)

FC13.4.2 Metabolomics and its role in predicting ADRs

Roy Goodacre (UK)

FC13.4.3 Use of Omics in understanding mechanisms of ADRs

Richard S Paules (USA)

FC13.4.4 Systems biology of drug metabolism

Urich M Zanger (Germany)

14:30 - 17:30 FC14 ADDICTION AND DOPING: NEUROBIOLOGICAL AND CLINICAL BASIS OF EMERGING TREATMENTS

Leaders: Markus Heilig (USA) & Yavin Shaham (USA)

FC14.4 The role of stress in the addictive process

Chairs: George F Koob (USA) & Markus Heilig (USA)

FC14.4.1 The role of stress systems and the amygdale in addictive disorders

George F Koob (USA)

FC14.4.2 Stress related neuropeptides: candidate treatment targets in alcoholism

Markus Heilig (USA)

FC14.4.3 Alcohol induced aggression: the role of CRH systems

Klaus A Miczek (USA)

FC14.4.4 The role of kappa-opioid transmission in dysphoric states related to stress and addiction

Charles Chavkin (USA)

Thursday, 22 July 2010

14:30 - 17:30 FC15 **ENDOTHELIUM IN HEALTH AND DISEASE**
Leaders: Christopher J Garland(UK) & Arthur Weston (UK)

FC15.4 **Drug development and novel therapeutic targets and approaches**
Chairs: Johannes-Peter Stasch (Germany) & Harald Schmidt (Australia)

FC15.4.1 Stimulators and activators of sGC: from bench to bedside
Johannes-Peter Stasch (Germany)

FC15.4.2 Gaseous signalling molecules: H₂S in the management of multiple hypoxic/ischemic conditions
Csaba Szabó (USA)

FC15.4.3 Therapeutic effects of enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling
Ulrich Förstermann (Germany)

FC15.4.4 NOX 1, 2, 3 and counting: targeting oxidative stress
Harald Schmidt (Australia)

14:30 - 17:30 FC16 **NATURAL PRODUCTS: PAST AND FUTURE?**
Leaders: Ricky Ying-Keung Man (PR China), Tai-Ping Fan (UK), & Zhi-bin Lin (PR China)

FC16.4 **East meets west: from prevention to therapy**
Chairs: Paul M Vanhoutte (PR China) & Arnold G Herman (Belgium)

FC16.4.1 Holistic treatment by traditional Chinese medicine
Tai-Ping Fan (UK)

FC16.4.2 Philosophy of Ayurvedic medicine
Arunabha Ray (India)

FC16.4.3 Contributions of plant-derived products to Western medicine
Arnold G Herman (Belgium)

FC16.4.4 Systems biology and the future of traditional medicine
Guoan Luo (PR China)

14:30 - 17:30 FC17 **NEW APPROACHES AND TARGETS IN PSYCHIATRY**
Leaders: David J Nutt (UK) & Birte Glenthøj (Denmark)

FC17.4 **Exploring new targets in affective disorders using translational science**
Chair: Christopher A Lowry (USA) & David J Nutt

FC17.4.1 Can we target specific neuronal populations to improve the efficacy and safety of antidepressants?
Christopher A Lowry (USA)

FC17.4.2 *In vivo* approaches in preclinical models
Arne Mørk (Denmark)

FC17.4.3 Using imaging as a translational tool for studying depression in humans
Catherine J Harmer (UK)

FC17.4.4 Understanding current antidepressants' action as a way to develop improved therapies
David J Nutt (UK)

Thursday, 22 July 2010

09:30 - 12:30 FC18 NUCLEAR RECEPTOR TARGETS FOR TREATMENT OF DISEASES

Leaders: Bart Staels (France) & Vincent Laudet (France)

FC18.4 The molecular basis of NR pharmacology

Chairs: Shigeaki Kato (Japan) & Vincent Laudet (France)

FC18.4.1 Structure of the intact PPAR- γ -RXR- α nuclear receptor complex on DNA
Fraydoon Rastinejad (USA)

FC18.4.2 Evolution and Pharmacology of LXR, PXR and FXRs
Matthew D Krasowski (USA) (TBC)

FC18.4.3 The role of co-regulators/co-regulator complexes in NR function
Shigeaki Kato (Japan)

FC18.4.4 Evolution of nuclear receptors and of their ligands
Vincent Laudet (France)

17:30 - 18:15 PL19 PLENARY LECTURE

PL19 Reversal of corticosteroid resistance in severe inflammatory diseases:
a novel therapeutic strategy
Peter J Barnes (UK)

17:30 - 18:15 PL20 PLENARY LECTURE

PL20 Role of the renin-angiotensin system in vascular inflammation
Ernesto Schiffrin (Canada)

17:30 - 18:15 PL21 EPHAR PLENARY LECTURE

PL21 EPHAR plenary lecture (title to be announced)
Thomas Lönnngren (Sweden)

18:30 EPHAR GENERAL ASSEMBLY

Friday, 23 July 2010

08:30 - 09:15 PL22 PLENARY LECTURE

PL22 New strategies for stroke prevention
Ding-Feng Su (PR China)

08:30 - 09:15 PL23 PLENARY LECTURE

PL23 Clinical pharmacology of Alzheimer's disease
Jean Marc Orgogozo (France)

08:30 - 09:15 PL24 PLENARY LECTURE

PL24 Pharmacology of organic nitrates: from 19th century homeopathy to genetic mouse models
Bernd Mayer (Austria)

09:30 - 12:30 FC10 DRUGS FOR HALF THE WORLD: PAEDIATRIC CLINICAL PHARMACOLOGY

Leader: John N van den Anker (USA)

FC10.5 Recent advance in paediatric clinical pharmacology

Chair: Shinya Ito (Canada)

FC10.5.1 Post-genomics pharmacogenetics in children
Evelyne Jacqz-Aigrain (France)

FC10.5.2 ADR pharmacogenetics
Bruce Carleton (Canada)

FC10.5.3 Population PK-guided simulation study in children exposed to drugs in human milk
Shinya Ito (Canada)

FC10.5.4 Use of biopharmaceuticals in children: efficacy and toxicities of monoclonal antibody for pediatric rheumatic diseases
Shunpei Yokota (Japan)

09:30 - 12:30 FC11 G PROTEIN-COUPLED 7TM RECEPTORS: FROM MOLECULAR TO PHYSIOLOGICAL FUNCTION

Leaders: Brian K Kobilka (USA) & Jean-Philippe Pin (France)

FC11.5 γ TM receptors: drug discovery and new physiological functions

Chairs: Hans Bräuner-Osborne (Denmark) & P Jeffrey Conn (USA)

FC11.5.1 Characterization of GPRC6A – a promiscuous γ TM receptor activated by basic L-amino acids
Hans Bräuner-Osborne (Denmark)

FC11.5.2 Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
P Jeffrey Conn (USA)

FC11.5.3 GPCRs as metabolite receptors
Stephan Offermanns (Germany)

FC11.5.4 A gut feeling for obesity: 7TM sensors on enteroendocrine cells
Birgitte Holst (Denmark)

Friday, 23 July 2010

09:30 - 12:30 FC12 ION CHANNELOPATHIES: NEW WINDOWS ON COMPLEX DISEASE AND THERAPY

Leader: William A Catterall (USA)

FC12.5 Ion channelopathies in lymphocytes: severe combined immunodeficiency and store-operated calcium channels

Chair: Michael D Cahalan (USA)

- FC12.5.1 Orai and stim in store-operated calcium release
Michael D Cahalan (USA)
- FC12.5.2 Diverse functions of STIM in store-operated calcium entry
Richard S Lewis (USA)
- FC12.5.3 Severe combined immunodeficiency syndrome
Stefan Feske (USA)
- FC12.5.4 Calcium signaling in lymphocytes
Anjana Rao (USA)

09:30 - 12:30 FC13 MAXIMISING BENEFITS AND MINIMIZING HARMS FROM DRUGS

Leaders: Munir Pirmohamed (UK) & B Kevin Park (UK)

FC13.5 New insights in the genetics of drug metabolism and action

Chairs: Magnus Ingelman-Sundberg (Sweden) & Richard M Weinshilboum (USA)

- FC13.5.1 Molecular mechanisms of altered drug response
Magnus Ingelman-Sundberg (Sweden)
- FC13.5.2 Genetic variability of adrenergic receptors
Ian P Hall (UK)
- FC13.5.3 Genetic variability of pain perception and treatment
Jörn Lötsch (Germany)
- FC13.5.4 Critical review of genotype-adapted drug therapy
Richard M Weinshilboum (USA)

09:30 - 12:30 FC14 ADDICTION AND DOPING: NEUROBIOLOGICAL AND CLINICAL BASIS OF EMERGING TREATMENTS

Leaders: Markus Heilig (USA) & Yavin Shaham (USA)

FC14.5 Doping - an underestimated problem with many unknowns

Chairs: Harrison G Pope (USA) & Anders Rane (Denmark)

- FC14.5.1 Societal aspects of doping
Harrison G Pope (USA)
- FC14.5.2 Anabolic steroid abuse: Insights from drug testing results
Gary I Wadler (Canada) (TBC)
- FC14.5.3 Morbidity and mortality in users of anabolic androgenic steroids
Ingmar Thiblin (Sweden)
- FC14.5.4 Anabolic steroid addiction: insights from animals and humans
Ruth I Wood (USA)

Friday, 23 July 2010

09:30 - 12:30 FC16 NATURAL PRODUCTS: PAST AND FUTURE?

Leaders: Ricky Ying-Keung Man (PR China), Tai-Ping Fan (UK), & Zhi-bin Lin (PR China)

FC16.5 Globalization of natural/traditional products

Chairs: Ricky Ying-Keung Man (PR China) & Monique Simmonds (UK)

- FC16.5.1 Geographical sustainability of natural products: as modelled by the Araliaceae family
Yuri N Zhuravlev (Russian Federation)
- FC16.5.2 Authentication of natural products
Monique Simmonds (UK)
- FC16.5.3 Standardization of natural products (chemical and biological finger printing)
Yung-chi (Tommy) Cheng (USA)
- FC16.5.4 Regulatory affairs
Josephine P Briggs (USA)

09:30 - 12:30 FC17 NEW APPROACHES AND TARGETS IN PSYCHIATRY

Leaders: David J Nutt (UK) & Birte Glenthøj (Denmark)

FC17.5 New pharmacological approaches for treatment of stress induced mood disorders

Chairs: Elisabeth B Binder (Germany) & Rosanio Leopardi (Switzerland)

- FC17.5.1 Using gene x environment interactions to target personalised treatment in mood disorder
Elisabeth B Binder (Germany)
- FC17.5.2 Mechanism and novel targets for effective treatment of stress disorder
Hans Reul (UK)
- FC17.5.3 Can brain mechanism in PTSD help direct treatment advances?
Eric Vermetten (the Netherlands)
- FC17.5.4 Treatment needs in psychosocial stress, exhaustion and depression
Rosanio Leopardi (Switzerland)

12:30 CLOSING CEREMONY